Back to resultsNew Methods to Measure the Immune Response to Hepatitis B Vaccine
Primary Purpose
Hepatitis B
Status
Completed
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
Hepatitis B vaccine
Sponsored by
About this trial
This is an interventional basic science trial for Hepatitis B
Eligibility Criteria
Inclusion Criteria:
All participants for both parts 1 and 2 must meet the following conditions in order to be enrolled:
- Participant is willing and able to give informed consent for participation in the study
- Healthy Male or Female, aged 18 - 60 years
- No allergies to the vaccine or its excipients
Participants enrolling in Part 1 must also meet the following conditions:
- Participant has previously received a primary immunisation course of HepB vaccine (3 primary doses). The 4th booster dose recommended after 12 months is not a requirement. There are a variety of possible recommended schedules, and any may have been used as long as the final vaccine (or booster vaccine) was given at least 12 months prior to the participant enrolling in the study.
- Participant is willing to allow their General Practitioner to be notified, if appropriate, of participation in the study
Participants enrolling in Part 2 must also meet the following conditions Participant receiving HBvaxPro® (the usual vaccine given within the Occupational Health Department).
Exclusion Criteria:
The participant may not enter either study if ANY of the following apply:
Have any known or suspected impairment or alteration of immune function, resulting from, for example:
- Congenital or acquired immunodeficiency (including IgA deficiency)
- Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition
- Autoimmune disease
- Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy.
- Chronic illness that could interfere with immunological function or donation of the required volumes of blood (e.g. cardiac or renal disease, diabetes, or auto-immune disorders).
- Receipt of a HepB booster vaccine within the past 12 months.
- Prior history of anaphylactic reaction to a previous dose of a Hepatitis B containing vaccine or known hypersensitivity to any vaccine component;
- Receipt of blood, blood products, or plasma derivatives within the past 3 months.
- Total blood donation greater than 50 ml within the past 3 months.
- Thrombocytopenia or any bleeding disorder.
- Pregnancy as confirmed by a positive pregnancy test, or currently breastfeeding.
- Receipt of a live vaccine within 4 weeks prior to vaccination or a killed vaccine within 7 days prior to vaccination.
- Plan to receive any vaccine other than the study vaccine within 4 weeks following vaccination.
- Enrolled in another study, which, in the opinion of the investigator, could compromise the integrity of either study being conducted.
- A member of staff on the delegation log
- According to the TOPS database, have recently taken part in a significant number of other studies, which, in the opinion of the investigator, warrant exclusion from further studies.
- Participant is a known non-responder to the HepB vaccine
- Have any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
- Unable to understand English, or what will be required from them during the study.
Sites / Locations
- Centre for Clinical Vaccinology & Tropical Medicine (CCVTM)
Outcomes
Primary Outcome Measures
Part 2- To assess B cell VH/L gene segment usage by HepB specific B cells during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months.
HepB specific cells will be isolated using magnetic-activated cell sorting, and fluorescence-activated cell sorting. VH/L gene segments will be amplified by PCR, and DNA prepared for sequencing. Bioinformatic approaches will then be used to create frequency tables of the different V, D and J exons that comprise these gene segments.
Part 1- To validate B cell assays and assess the kinetics of HepB specific B cell subsets following administration of a booster dose of HepB vaccine given to previously immunised healthy adults.
HepB specific B cell subsets will be identified using both ELISPOT and flow cytometry.
Secondary Outcome Measures
Part 1 • To measure HepB surface antigen-specific antibody concentration following administration of a booster dose of HepB vaccine given to previously immunised healthy adults
Antibody concentrations will be determined from blood plasma using an ELISA
Part 1 • To assess B-cell receptor VH/L gene sequences used in HepB specific and non-antigen specific B-cells prior to and following administration of a booster dose of HepB vaccine given to previously immunised healthy adults
VH/L gene segments will be amplified by PCR, and DNA prepared for sequencing. Bioinformatic approaches will then be used to create frequency tables of the different V, D and J exons that comprise these gene segments.
Part 1 • Comparison of B cell receptor VH/L gene segment usage as determined by two different next-generation sequencing methods (RNA-sequencing and 454).
Different sequencing protocols introduce different types of error and bias into the resulting sequence datasets. VH/L gene segments will sequenced using two different techniques. Bioinformatic approaches and descriptive analysis will then be used to compare the effects of the two different protocols. Frequency tables of the different V, D and J exons that comprise these gene segments will be generated, for comparison.
Part 1 • Collection of mRNA for subsequent gene expression analysis
Part 2 • To measure HepB specific plasma and memory B cell frequencies during and following administration of a three dose course of HepB vaccine given at 0, 1, 2 or 0, 1, 6 months.
HepB specific B cell subsets will be identified using both ELISPOT and flow cytometry.
Part 2 • To measure HepB surface antigen-specific antibody concentration during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months.
Antibody concentrations will be determined from blood plasma using an ELISA
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01821547
Brief Title
New Methods to Measure the Immune Response to Hepatitis B Vaccine
Official Title
Hepatitis B Immunisation: A Two-part Study Investigating Antigen Specific B Cell Receptors
Study Type
Interventional
2. Study Status
Record Verification Date
June 2016
Overall Recruitment Status
Completed
Study Start Date
March 2013 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
May 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oxford
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Hepatitis B vaccine is a safe and effective vaccine used widely throughout the world. Because of this it is a useful vaccine in which to develop new methods for studying immune responses. Measuring the immune response to vaccines helps us to understand how they work and whether they are likely to protect any individual against infection. For most vaccines we measure the immune system's production of antibody after a vaccine has been given. The investigators want to develop new methods that give a far more detailed picture of the antibody response to vaccines than has previously been possible. These methods will investigate the genetic instructions used by each antibody producing cell to make antibody. These methods have the potential to give new insights into the way vaccines work, which could be applied to studying vaccines and vaccine schedules in the future.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis B
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Hepatitis B vaccine
Other Intervention Name(s)
HBvaxPRO, 10μg/ml, Sanofi Pastuer
Intervention Description
Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
Primary Outcome Measure Information:
Title
Part 2- To assess B cell VH/L gene segment usage by HepB specific B cells during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months.
Description
HepB specific cells will be isolated using magnetic-activated cell sorting, and fluorescence-activated cell sorting. VH/L gene segments will be amplified by PCR, and DNA prepared for sequencing. Bioinformatic approaches will then be used to create frequency tables of the different V, D and J exons that comprise these gene segments.
Time Frame
0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation
Title
Part 1- To validate B cell assays and assess the kinetics of HepB specific B cell subsets following administration of a booster dose of HepB vaccine given to previously immunised healthy adults.
Description
HepB specific B cell subsets will be identified using both ELISPOT and flow cytometry.
Time Frame
0, 7, 14, 21 and 28 days after immunisation
Secondary Outcome Measure Information:
Title
Part 1 • To measure HepB surface antigen-specific antibody concentration following administration of a booster dose of HepB vaccine given to previously immunised healthy adults
Description
Antibody concentrations will be determined from blood plasma using an ELISA
Time Frame
0 and 28 days after immunisation
Title
Part 1 • To assess B-cell receptor VH/L gene sequences used in HepB specific and non-antigen specific B-cells prior to and following administration of a booster dose of HepB vaccine given to previously immunised healthy adults
Description
VH/L gene segments will be amplified by PCR, and DNA prepared for sequencing. Bioinformatic approaches will then be used to create frequency tables of the different V, D and J exons that comprise these gene segments.
Time Frame
0, 7, 14, 21 and 28 days after immunisation
Title
Part 1 • Comparison of B cell receptor VH/L gene segment usage as determined by two different next-generation sequencing methods (RNA-sequencing and 454).
Description
Different sequencing protocols introduce different types of error and bias into the resulting sequence datasets. VH/L gene segments will sequenced using two different techniques. Bioinformatic approaches and descriptive analysis will then be used to compare the effects of the two different protocols. Frequency tables of the different V, D and J exons that comprise these gene segments will be generated, for comparison.
Time Frame
0, 7, 14, 21 and 28 days after immunisation, as required
Title
Part 1 • Collection of mRNA for subsequent gene expression analysis
Time Frame
0, 7, 14, 21 and 28 days after immunisation
Title
Part 2 • To measure HepB specific plasma and memory B cell frequencies during and following administration of a three dose course of HepB vaccine given at 0, 1, 2 or 0, 1, 6 months.
Description
HepB specific B cell subsets will be identified using both ELISPOT and flow cytometry.
Time Frame
0 and 7 days after the second immunisation, and 0, 7 and 40 days after the third immunisation
Title
Part 2 • To measure HepB surface antigen-specific antibody concentration during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months.
Description
Antibody concentrations will be determined from blood plasma using an ELISA
Time Frame
0 days after the second immunisation, and 0 and 40 days after the third immunisation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
All participants for both parts 1 and 2 must meet the following conditions in order to be enrolled:
Participant is willing and able to give informed consent for participation in the study
Healthy Male or Female, aged 18 - 60 years
No allergies to the vaccine or its excipients
Participants enrolling in Part 1 must also meet the following conditions:
Participant has previously received a primary immunisation course of HepB vaccine (3 primary doses). The 4th booster dose recommended after 12 months is not a requirement. There are a variety of possible recommended schedules, and any may have been used as long as the final vaccine (or booster vaccine) was given at least 12 months prior to the participant enrolling in the study.
Participant is willing to allow their General Practitioner to be notified, if appropriate, of participation in the study
Participants enrolling in Part 2 must also meet the following conditions Participant receiving HBvaxPro® (the usual vaccine given within the Occupational Health Department).
Exclusion Criteria:
The participant may not enter either study if ANY of the following apply:
Have any known or suspected impairment or alteration of immune function, resulting from, for example:
Congenital or acquired immunodeficiency (including IgA deficiency)
Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition
Autoimmune disease
Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy.
Chronic illness that could interfere with immunological function or donation of the required volumes of blood (e.g. cardiac or renal disease, diabetes, or auto-immune disorders).
Receipt of a HepB booster vaccine within the past 12 months.
Prior history of anaphylactic reaction to a previous dose of a Hepatitis B containing vaccine or known hypersensitivity to any vaccine component;
Receipt of blood, blood products, or plasma derivatives within the past 3 months.
Total blood donation greater than 50 ml within the past 3 months.
Thrombocytopenia or any bleeding disorder.
Pregnancy as confirmed by a positive pregnancy test, or currently breastfeeding.
Receipt of a live vaccine within 4 weeks prior to vaccination or a killed vaccine within 7 days prior to vaccination.
Plan to receive any vaccine other than the study vaccine within 4 weeks following vaccination.
Enrolled in another study, which, in the opinion of the investigator, could compromise the integrity of either study being conducted.
A member of staff on the delegation log
According to the TOPS database, have recently taken part in a significant number of other studies, which, in the opinion of the investigator, warrant exclusion from further studies.
Participant is a known non-responder to the HepB vaccine
Have any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
Unable to understand English, or what will be required from them during the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominic Kelly
Organizational Affiliation
Oxford Vaccine Group
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre for Clinical Vaccinology & Tropical Medicine (CCVTM)
City
Oxford
State/Province
Oxfordshire
ZIP/Postal Code
OX3 7LE
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
New Methods to Measure the Immune Response to Hepatitis B Vaccine
We'll reach out to this number within 24 hrs